Different human papillomavirus types share early natural history transitions in immunocompetent women

Sally N. Adebamowo & Nicole G Campos et al. · 2022-06-17

Abstract

Necessary stages of cervical carcinogenesis include acquisition of a carcinogenic human papillomavirus (HPV) type, persistence associated with the development of precancerous lesions, and invasion. Using prospective data from immunocompetent women in the Guanacaste HPV Natural History Study (NHS), the ASCUS‐LSIL Triage Study (ALTS) and the Costa Rica HPV Vaccine Trial (CVT), we compared the early natural history of HPV types to inform transition probabilities for health decision models. We excluded women with evidence of high‐grade cervical abnormalities at any point during follow‐up and restricted the analysis to incident infections in all women and prevalent infections in young women (aged <30 years). We used survival approaches accounting for interval‐censoring to estimate the time to clearance distribution for 20 529 HPV infections (64% were incident and 51% were carcinogenic). Time to clearance was similar across HPV types and risk classes (HPV16, HPV18/45, HPV31/33/35/52/58, HPV 39/51/56/59 and noncarcinogenic HPV types); and by age group (18‐29, 30‐44 and 45‐54 years), among carcinogenic and noncarcinogenic infections. Similar time to clearance across HPV types suggests that relative prevalence can predict relative incidence. We confirmed that there was a uniform linear association between incident and prevalent infections for all HPV types within each study cohort. In the absence of progression to precancer, we observed similar time to clearance for incident infections across HPV types and risk classes. A singular clearance function for incident HPV infections has important implications for the refinement of microsimulation models used to evaluate the cost‐effectiveness of novel prevention technologies.

Funding
RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUSRANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OFAfrican Collaborative Center for Microbiome and Genomics Research (ACCME)RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUS ANDComprehensive Polygenic Risk Profiling Across Multiple Health Outcomes (CARDINAL)UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTRANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUS ANDNCI NIH HHS Grant N01 CP011005RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUS ANDCLINICAL MANAGEMENT OF ASCUS/LSIL OF THE UTERINE CERVIXDeveloping Data-Driven Cancer ResearchersCLINICAL MANAGEMENT OF ASCUS/LSIL OF THE UTERINE CERVIXRANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OF ASCUSWorld Health Organization Grant 001RANDOMIZED TRIAL ON THE CLINICAL MANAGEMENT OFAmerican Cancer Society Grant IRG‐18‐160‐16National Cancer Institute Grant T32CA09168African Collaborative Center for Microbiome and Genomics Research (ACCME)UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTComprehensive Polygenic Risk Profiling Across Multiple Health Outcomes (CARDINAL)U.S. Department of Health and Human Services Grant CN‐55153U.S. Department of Health and Human Services Grant CN‐55154U.S. Department of Health and Human Services Grant CN‐55156U.S. Department of Health and Human Services Grant CN‐55157U.S. Department of Health and Human Services Grant CN‐55158U.S. Department of Health and Human Services Grant CN‐55159U.S. Department of Health and Human Services Grant CN55105U.S. Department of Health and Human Services Grant CN55155

NCI NIH HHS

N01 CN055159

NCI NIH HHS

N01 CN055158

NHGRI NIH HHS

U54 HG006947

NCI NIH HHS

N01 CN055156

NHGRI NIH HHS

U01 HG011717

NCI NIH HHS

P30 CA134274

NCI NIH HHS

N01 CN055154

NCI NIH HHS

N01 CN055155

NCI NIH HHS

N01 CN055153

NCI NIH HHS

T32 CA009168

NCI NIH HHS

N01 CN055157

NCI NIH HHS

N01 CN055105

National Human Genome Research Institute

1U54HG006947

National Human Genome Research Institute

P30CA134274

National Human Genome Research Institute

U01HG011717